MA29806B1 - Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques - Google Patents
Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiquesInfo
- Publication number
- MA29806B1 MA29806B1 MA30782A MA30782A MA29806B1 MA 29806 B1 MA29806 B1 MA 29806B1 MA 30782 A MA30782 A MA 30782A MA 30782 A MA30782 A MA 30782A MA 29806 B1 MA29806 B1 MA 29806B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- aminothiazoles
- derivatives
- processes
- aminooxazoles
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
- C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D419/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'INVENTION CONCERNE DES DÉRIVÉS DE 2-AMINOTHIAZOLES ET 2-AMINOOXAZOLES SOUS TOUTES LEURS FORMES STÉRÉOISOMÈRES, ÉNANTIOMÈRES ET DE MÉLANGES DANS N'IMPORTE QUEL RAPPORT, LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LES FORMES TAUTOMÈRES DE DEUX-CI QUI EXERCENT UNE ACTIVITÉ AGONISTE SUR LES RÉCEPTEURS PPAR$G(D). L'INVENTION DÉCRIT AINSI DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE (I), DANS LAQUELLE LES RADICAUX SONT TELS QUE DÉFINIS DANS LA DESCRIPTION, AINSI QUE LES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE CEUX-CI ET LES PROCÉDÉS UTILISÉS POUR LES OBTENIR. CES COMPOSÉS SONT UTILISÉS POUR TRAITER ET/OU PRÉVENIR LES TROUBLES DU MÉTABOLISME DES ACIDES GRAS, LES TROUBLES DE L'UTILISATION DU GLUCOSE, LES TROUBLES IMPLIQUANT L'INSULINORÉSISTANCE ET LA DÉMYÉLINISATION, AINSI QUE D'AUTRES TROUBLES NEURODÉGÉNÉRATIFS DU SYSTÈME NERVEUX CENTRAL ET PÉRIPHÉRIQUE
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05021279 | 2005-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA29806B1 true MA29806B1 (fr) | 2008-09-01 |
Family
ID=35764446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA30782A MA29806B1 (fr) | 2005-09-29 | 2008-03-24 | Derives de 2-aminothiazoles et 2- aminooxazoles,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7655679B2 (fr) |
| EP (1) | EP1931659B1 (fr) |
| JP (1) | JP2009509987A (fr) |
| KR (1) | KR20080048510A (fr) |
| CN (1) | CN101277953A (fr) |
| AR (1) | AR056542A1 (fr) |
| AT (1) | ATE480536T1 (fr) |
| AU (1) | AU2006299090A1 (fr) |
| BR (1) | BRPI0616477A2 (fr) |
| CA (1) | CA2624100A1 (fr) |
| DE (1) | DE602006016830D1 (fr) |
| IL (1) | IL190230A0 (fr) |
| MA (1) | MA29806B1 (fr) |
| MY (1) | MY148883A (fr) |
| NO (1) | NO20081368L (fr) |
| NZ (1) | NZ566876A (fr) |
| RU (1) | RU2008112199A (fr) |
| TW (1) | TW200732328A (fr) |
| UY (1) | UY29832A1 (fr) |
| WO (1) | WO2007039176A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008327106B2 (en) | 2007-11-20 | 2012-10-04 | Sumitomo Chemical Company, Limited | Pyridine compound, pesticidal composition and method of controlling pest |
| US9073881B2 (en) | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
| WO2013066839A2 (fr) * | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Composés et procédés |
| BR112021024165A2 (pt) * | 2019-05-31 | 2022-04-26 | Avolynt | Composições e métodos para o tratamento de doenças metabólicas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641796A (en) | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| GB9919413D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| AU2003224632A1 (en) * | 2002-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Hppars activators |
| US6653334B1 (en) | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
| DE602004004631D1 (de) | 2004-04-01 | 2007-03-22 | Sanofi Aventis Deutschland | Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika |
-
2006
- 2006-09-26 WO PCT/EP2006/009302 patent/WO2007039176A1/fr not_active Ceased
- 2006-09-26 CA CA002624100A patent/CA2624100A1/fr not_active Abandoned
- 2006-09-26 AU AU2006299090A patent/AU2006299090A1/en not_active Abandoned
- 2006-09-26 NZ NZ566876A patent/NZ566876A/en not_active IP Right Cessation
- 2006-09-26 KR KR1020087007472A patent/KR20080048510A/ko not_active Withdrawn
- 2006-09-26 CN CNA2006800360458A patent/CN101277953A/zh active Pending
- 2006-09-26 AT AT06792250T patent/ATE480536T1/de not_active IP Right Cessation
- 2006-09-26 DE DE602006016830T patent/DE602006016830D1/de active Active
- 2006-09-26 BR BRPI0616477-3A patent/BRPI0616477A2/pt not_active IP Right Cessation
- 2006-09-26 RU RU2008112199/04A patent/RU2008112199A/ru not_active Application Discontinuation
- 2006-09-26 EP EP06792250A patent/EP1931659B1/fr active Active
- 2006-09-26 JP JP2008532646A patent/JP2009509987A/ja not_active Abandoned
- 2006-09-27 TW TW095135659A patent/TW200732328A/zh unknown
- 2006-09-27 MY MYPI20064226A patent/MY148883A/en unknown
- 2006-09-27 AR ARP060104224A patent/AR056542A1/es not_active Application Discontinuation
- 2006-09-29 UY UY29832A patent/UY29832A1/es not_active Application Discontinuation
-
2008
- 2008-03-14 NO NO20081368A patent/NO20081368L/no not_active Application Discontinuation
- 2008-03-17 IL IL190230A patent/IL190230A0/en unknown
- 2008-03-24 MA MA30782A patent/MA29806B1/fr unknown
- 2008-03-26 US US12/055,771 patent/US7655679B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080227834A1 (en) | 2008-09-18 |
| BRPI0616477A2 (pt) | 2011-06-21 |
| TW200732328A (en) | 2007-09-01 |
| EP1931659B1 (fr) | 2010-09-08 |
| EP1931659A1 (fr) | 2008-06-18 |
| KR20080048510A (ko) | 2008-06-02 |
| MY148883A (en) | 2013-06-14 |
| CN101277953A (zh) | 2008-10-01 |
| UY29832A1 (es) | 2007-04-30 |
| NZ566876A (en) | 2010-05-28 |
| ATE480536T1 (de) | 2010-09-15 |
| DE602006016830D1 (de) | 2010-10-21 |
| US7655679B2 (en) | 2010-02-02 |
| CA2624100A1 (fr) | 2007-04-12 |
| WO2007039176A1 (fr) | 2007-04-12 |
| AR056542A1 (es) | 2007-10-10 |
| RU2008112199A (ru) | 2009-10-10 |
| NO20081368L (no) | 2008-06-18 |
| JP2009509987A (ja) | 2009-03-12 |
| IL190230A0 (en) | 2008-11-03 |
| AU2006299090A1 (en) | 2007-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA29807B1 (fr) | Dérives de phenyl-[1,2,4]- oxadiazol-5-one avec un groupement phényle, leurs procédés de préparation et leur utilisation comme produits pharmaceutiques. | |
| MA29805B1 (fr) | Derives de phenyl-1.2.4-oxadiazolone, leurs procedes de preparation et leur utilisation comme produits pharmaceutiques | |
| MA30981B1 (fr) | Derives de sulfonyl-phenyl-2h-(1,2,4)oxadiazol-5-one, procedes de preparation associes et utilisation comme medicaments | |
| MA29809B1 (fr) | N-[1,3,4]-thiadiazol-2-yl-benzenesulfonamides,procedes pour leur preparation et leur utilisation en tant que produits pharmaceutiques | |
| MA32705B1 (fr) | Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation | |
| MA31865B1 (fr) | Dérivés isoxazolo-pyridine | |
| MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| MA30696B1 (fr) | Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA33152B1 (fr) | Dérivés 1-hétérocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one et leur utilisation en tant que modulateurs de pde9a | |
| MA47447B1 (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA34359B1 (fr) | Dérivés de carbamate d'hexafluoroisopropyle, leur préparation et leur application thérapeutique | |
| MA29810B1 (fr) | 4-oxy-n-[1,3,4]-thiadiazol-2-yl-benzènesulfonamides, procédés pour leur préparation et leur utilisation en tant que produits pharmaceutiques | |
| TNSN04156A1 (fr) | Pyridinones substituees servant de modulateurs de la map-kinase p38 | |
| MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
| MA45223A (fr) | Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| MA42442B1 (fr) | Dérivés d'éthynyle comme modulateurs du récepteur métabotropique au glutamate | |
| MA29759B1 (fr) | 1h-imidazopyridines a substituant hydroxy et procedes | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA35422B1 (fr) | Imidazopyridazines amino-substituees | |
| MA31857B1 (fr) | N-phenyl-pyrrolidinylmethylpyrrolidine-amides substitues et utilisation therapeutique de ceux -ci | |
| MA30089B1 (fr) | (arylsulfonyl)-pyrasolopiperidines | |
| MA27775A1 (fr) | Composes organiques | |
| MA32108B1 (fr) | Derives d'indazole |